AU6193699A - Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1 - Google Patents

Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Info

Publication number
AU6193699A
AU6193699A AU61936/99A AU6193699A AU6193699A AU 6193699 A AU6193699 A AU 6193699A AU 61936/99 A AU61936/99 A AU 61936/99A AU 6193699 A AU6193699 A AU 6193699A AU 6193699 A AU6193699 A AU 6193699A
Authority
AU
Australia
Prior art keywords
nucleic acids
antisense nucleic
expression
adhesion molecule
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61936/99A
Inventor
Rainer Haas
Ralf Kronenwett
Volker Patzel
Georg Sczakiel
Ulrich Steidl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19844111A external-priority patent/DE19844111A1/en
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of AU6193699A publication Critical patent/AU6193699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to specific antisense nucleic acids which inhibit or regulate the expression of the adhesion molecule ICAM-1 in mammalian cells, notably human cells, to vectors and host cells containing these antisense nucleic acids and to pharmaceutical compositions which contain said antisense nucleic acids and are designed to control or treat, for example, acute or chronic inflammatory diseases. The invention also relates to diagnostic kits containing the above antisense nucleic acids.
AU61936/99A 1998-09-25 1999-09-21 Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1 Abandoned AU6193699A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE19844111 1998-09-25
DE19844111A DE19844111A1 (en) 1998-09-25 1998-09-25 Novel antisense nucleic acids targeted to specific sequences within the ICAM-1 gene, useful for treating inflammation and metastasis
DE19856138 1998-12-04
DE19856138 1998-12-04
DE19926110 1999-06-08
DE19926110 1999-06-08
PCT/EP1999/006972 WO2000018907A2 (en) 1998-09-25 1999-09-21 Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Publications (1)

Publication Number Publication Date
AU6193699A true AU6193699A (en) 2000-04-17

Family

ID=27218700

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61936/99A Abandoned AU6193699A (en) 1998-09-25 1999-09-21 Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Country Status (6)

Country Link
EP (1) EP1115858B1 (en)
AT (1) ATE236250T1 (en)
AU (1) AU6193699A (en)
DE (1) DE59904870D1 (en)
ES (1) ES2196864T3 (en)
WO (1) WO2000018907A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109810A2 (en) * 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
GB201700257D0 (en) 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New formulation
GB201700261D0 (en) * 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New therapeutic uses
JP7153947B2 (en) 2017-07-28 2022-10-17 ウニヴェルジテート ツー リューベック Antisense drug against canine ICAM-1 used for treatment of oral inflammation
US20220106601A1 (en) * 2019-01-25 2022-04-07 Universität Zu Lübeck Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1)
EP3685824A1 (en) * 2019-01-25 2020-07-29 Breitenbronn-Consulting GbR Composition for administering and releasing oligonucleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE231915T1 (en) * 1992-09-02 2003-02-15 Isis Pharmaceuticals Inc INFLUENCING CELL ADHESIA BY OLIGONUCLEOTIDES
EP0755402B1 (en) * 1994-04-13 2008-05-14 Biotransplant, Inc Alpha(1,3) galactosyltransferase negative swine
CA2273203A1 (en) * 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules

Also Published As

Publication number Publication date
EP1115858A2 (en) 2001-07-18
ATE236250T1 (en) 2003-04-15
DE59904870D1 (en) 2003-05-08
EP1115858B1 (en) 2003-04-02
WO2000018907A2 (en) 2000-04-06
ES2196864T3 (en) 2003-12-16
WO2000018907A3 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
ATE269402T1 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
Nilsen-Hamilton et al. Selective stimulation by mitogens of incorporation of 35S-methionine into a family of proteins released into the medium by 3T3 cells
ATE334657T1 (en) INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES
AU1458395A (en) Composition containing nucleic acids, preparation and uses
ATE418563T1 (en) NIK PROTEINS, NUCLEIC ACID AND METHODS
EP0883344A4 (en) Therapeutic molecules generated by trans-splicing
AU9016998A (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
MY135913A (en) Fsh and fsh variant formulations comprising benzyl alcohol as a preservative
ATE275956T1 (en) ALTERATION OF DNA METHYLTRANSFERASE THROUGH COMBINATION THERAPY
DE69808743D1 (en) Netrinrezeptoren
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
AU7548500A (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
DE69826493D1 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
BR9813917A (en) Hyperthermic inducible expression vectors for gene therapy and methods of using them
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
BR9811014A (en) "concentrated gene regulatory region specifically for early seed"
HUP9904413A2 (en) Purified proteins, recombinant dna sequences and processes for controlling the ripening of coffee plants
DE60044038D1 (en) XYLOSYLTRANSFERASE AND ISOFORMS
Miyata et al. Analysis of gene expression in homocysteine-injured vascular endothelial cells: demonstration of GRP78/BiP expression, cloning and characterization of a novel reducing agent-tunicamycin regulated gene
Yanagisawa et al. Alteration of a DNA-dependent ATPase activity in xeroderma pigmentosum complementation group C cells.
McClelland et al. The calpain—calpastatin system in vascular smooth muscle
AU2001235696A1 (en) Compositions useful for regulating parkin gene activity
DE60333747D1 (en) DNA ENZYME FOR INHIBITING PLASMINOGENACTIVATOR INHIBITOR-1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase